A detailed history of State Street Corp transactions in Cytosorbents Corp stock. As of the latest transaction made, State Street Corp holds 140,293 shares of CTSO stock, worth $129,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares
140,293
Previous 140,293 -0.0%
Holding current value
$129,069
Previous $98,000 114.29%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.86 - $1.07 $9,288 - $11,556
-10,800 Reduced 7.15%
140,293 $133,000
Q2 2023

Aug 14, 2023

SELL
$2.37 - $3.65 $2,133 - $3,285
-900 Reduced 0.59%
151,093 $542,000
Q4 2022

Feb 14, 2023

SELL
$1.03 - $2.03 $5,768 - $11,367
-5,600 Reduced 3.55%
151,993 $235,000
Q2 2022

Aug 15, 2022

SELL
$1.76 - $3.22 $994,568 - $1.82 Million
-565,096 Reduced 78.19%
157,593 $345,000
Q1 2022

May 16, 2022

BUY
$2.88 - $4.23 $5,474 - $8,041
1,901 Added 0.26%
722,689 $2.31 Million
Q4 2021

Feb 14, 2022

SELL
$4.05 - $8.11 $4,774 - $9,561
-1,179 Reduced 0.16%
720,788 $3.02 Million
Q3 2021

Nov 15, 2021

BUY
$7.0 - $9.71 $52,899 - $73,378
7,557 Added 1.06%
721,967 $5.86 Million
Q2 2021

Aug 16, 2021

BUY
$7.55 - $9.42 $427,511 - $533,398
56,624 Added 8.61%
714,410 $5.39 Million
Q1 2021

May 17, 2021

BUY
$8.23 - $11.48 $110,084 - $153,556
13,376 Added 2.08%
657,786 $5.71 Million
Q4 2020

Feb 16, 2021

BUY
$7.65 - $8.98 $238,527 - $279,996
31,180 Added 5.08%
644,410 $5.14 Million
Q3 2020

Nov 10, 2020

BUY
$7.37 - $11.54 $395,164 - $618,751
53,618 Added 9.58%
613,230 $4.89 Million
Q2 2020

Aug 14, 2020

BUY
$6.28 - $10.59 $128,928 - $217,412
20,530 Added 3.81%
559,612 $5.54 Million
Q1 2020

May 11, 2020

BUY
$3.77 - $7.73 $2.03 Million - $4.17 Million
539,082 New
539,082 $4.17 Million

Others Institutions Holding CTSO

About Cytosorbents Corp


  • Ticker CTSO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 43,577,400
  • Market Cap $40.1M
  • Description
  • Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...
More about CTSO
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.